PACE trial: What Menarini’s biomarker data reveals about escalating treatment in metastatic breast cancer
Menarini Silicon Biosystems has reported new secondary analysis results from the PACE trial, reinforcing the potential of its CELLSEARCH Circulating Tumor Cell (CTC) enumeration system as a predictive biomarker for guiding treatment escalation in hormone receptor-positive, HER2-negative metastatic breast cancer. Published in Clinical Cancer Research, the findings suggest that CTC counts in blood samples could […]